vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
vTv Therapeutics (VTVT) has appointed Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer. Dr. Tung brings 20 years of experience in finance, corporate strategy, and business development in the biopharmaceutical industry. The appointment coincides with the company's reinitiation of the CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes (T1D) treatment.
Prior to joining vTv, Dr. Tung served as CFO of AdvanCell Pty Limited and held senior positions at FibroGen Inc. and Aclaris Therapeutics. He holds B.A. and B.S. degrees in economics and biology from The George Washington University and a combined M.D./M.B.A. from Tufts University School of Medicine.
vTv Therapeutics (VTVT) ha nominato Michael Tung, M.D., MBA come Vicepresidente Esecutivo e Direttore Finanziario. Il dottor Tung porta con sé 20 anni di esperienza in finanza, strategia aziendale e sviluppo commerciale nel settore biofarmaceutico. La nomina coincide con la ripresa da parte dell'azienda dello studio di Fase 3 CATT1 per cadisegliatin, una potenziale terapia orale adiuvante alla insulina, prima nel suo genere, per il trattamento del diabete di tipo 1 (T1D).
Prima di entrare in vTv, il dottor Tung è stato CFO di AdvanCell Pty Limited e ha ricoperto ruoli senior presso FibroGen Inc. e Aclaris Therapeutics. Ha conseguito lauree in economia e biologia presso la George Washington University e un titolo combinato M.D./M.B.A. presso la Tufts University School of Medicine.
vTv Therapeutics (VTVT) ha nombrado a Michael Tung, M.D., MBA como Vicepresidente Ejecutivo y Director Financiero. El Dr. Tung aporta 20 años de experiencia en finanzas, estrategia corporativa y desarrollo comercial en la industria biofarmacéutica. Este nombramiento coincide con la reanudación por parte de la compañía del ensayo de Fase 3 CATT1 para cadisegliatin, una posible terapia oral adyuvante a la insulina de primera clase para el tratamiento de la diabetes tipo 1 (T1D).
Antes de unirse a vTv, el Dr. Tung fue CFO de AdvanCell Pty Limited y ocupó cargos senior en FibroGen Inc. y Aclaris Therapeutics. Posee títulos en economía y biología de la Universidad George Washington y un M.D./M.B.A. combinado de la Facultad de Medicina de la Universidad de Tufts.
vTv Therapeutics (VTVT)는 Michael Tung, M.D., MBA를 부사장 겸 최고재무책임자(CFO)로 임명했습니다. Tung 박사는 생명공학 제약 산업에서 20년간 금융, 기업 전략 및 사업 개발 경험을 보유하고 있습니다. 이번 임명은 회사가 cadisegliatin의 CATT1 3상 시험을 재개하는 시점과 맞물립니다. cadisegliatin은 제1형 당뇨병(T1D) 치료를 위한 인슐린 보조 경구용 신약 후보입니다.
vTv에 합류하기 전 Tung 박사는 AdvanCell Pty Limited의 CFO를 역임했으며 FibroGen Inc.와 Aclaris Therapeutics에서 고위직을 맡았습니다. 그는 조지 워싱턴 대학교에서 경제학과 생물학 학사 학위를, 터프츠 대학교 의과대학에서 M.D./M.B.A. 복수 학위를 취득했습니다.
vTv Therapeutics (VTVT) a nommé Michael Tung, M.D., MBA au poste de Vice-Président Exécutif et Directeur Financier. Le Dr Tung apporte 20 ans d'expérience en finance, stratégie d'entreprise et développement commercial dans l'industrie biopharmaceutique. Cette nomination coïncide avec la reprise par la société de l'essai de Phase 3 CATT1 pour le cadisegliatin, une thérapie orale adjuvante potentielle de première classe à l'insuline pour le traitement du diabète de type 1 (T1D).
Avant de rejoindre vTv, le Dr Tung a été CFO d'AdvanCell Pty Limited et a occupé des postes de direction chez FibroGen Inc. et Aclaris Therapeutics. Il détient des diplômes en économie et biologie de l'Université George Washington ainsi qu'un M.D./M.B.A. combiné de la Faculté de Médecine de l'Université Tufts.
vTv Therapeutics (VTVT) hat Michael Tung, M.D., MBA zum Executive Vice President und Chief Financial Officer ernannt. Dr. Tung bringt 20 Jahre Erfahrung in Finanzen, Unternehmensstrategie und Geschäftsentwicklung in der biopharmazeutischen Industrie mit. Die Ernennung fällt mit der Wiederaufnahme der CATT1 Phase-3-Studie für Cadisegliatin zusammen, einer potenziellen erstmaligen oralen Zusatztherapie zu Insulin zur Behandlung von Typ-1-Diabetes (T1D).
Vor seinem Wechsel zu vTv war Dr. Tung CFO bei AdvanCell Pty Limited und bekleidete leitende Positionen bei FibroGen Inc. und Aclaris Therapeutics. Er besitzt einen B.A. und B.S. in Wirtschaft und Biologie von der George Washington University sowie einen kombinierten M.D./M.B.A. von der Tufts University School of Medicine.
- Appointment of highly qualified CFO with 20 years of industry experience and relevant healthcare background
- Reinitiation of Phase 3 trial for potentially first-in-class T1D treatment
- Strategic timing of executive appointment coinciding with critical clinical development phase
- None.
Insights
vTv's Phase 3 restart for cadisegliatin, potentially first oral T1D adjunct to insulin, represents meaningful clinical progress despite CFO change.
vTv Therapeutics has made two significant announcements that deserve investor attention. First, they've reinitiated screening in their CATT1 Phase 3 trial for cadisegliatin, which is being developed as a first-in-class oral adjunctive therapy to insulin for type 1 diabetes (T1D). This restart indicates the company has addressed previous hurdles that may have delayed the program.
The therapeutic positioning is notable - cadisegliatin would be among the first oral medications designed specifically as an adjunct to insulin in T1D, a disease historically limited to insulin as the primary treatment option. This creates a potential market opportunity addressing a significant unmet need. Type 1 diabetes affects approximately
Regarding management, vTv has appointed Dr. Michael Tung as EVP and CFO. His background combines medical training (licensed physician) with financial expertise (MBA, portfolio management experience) and industry-specific roles at FibroGen, Aclaris, and AdvanCell. This dual expertise is valuable for a clinical-stage biotech company navigating both complex clinical development and capital markets.
The timing of this CFO appointment aligns with the Phase 3 restart, suggesting the company is positioning itself for a critical period requiring strong financial leadership. While executive changes sometimes signal organizational shifts, this appears to be a strategic enhancement rather than a concerning departure. Phase 3 trials typically represent the most capital-intensive stage of drug development, necessitating experienced financial oversight.
HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry. This executive appointment comes at an important time for the Company, which recently reinitiated screening in its CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D).
“Michael is an experienced financial executive who will be instrumental in shaping our strategy and brings robust capital markets expertise, established relationships within the financial community, and a deep understanding of the industry landscape to vTv,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. “We are excited to welcome him to the executive team at this critical inflection point for vTv as we further advance our cadisegliatin program.”
“I am honored to join the vTv Therapeutics team at this stage in its evolution as the Company reinitiates its CATT1 Phase 3 trial and continues its work to benefit patients with type one diabetes.” Dr. Tung added, “I look forward to collaborating with the team to enhance shareholder value while leveraging my financial experience to help the Company achieve its development goals and execute its strategic vision.”
Michael brings more than 20 years of financial management, investment experience, and strategic leadership for both private and public companies in the life sciences industry. Prior to joining vTv Therapeutics, Dr. Tung most recently served as Chief Financial Officer of AdvanCell Pty Limited. He also held senior level positions in corporate strategy and investor relations at FibroGen Inc. and Aclaris Therapeutics. Earlier in his career, he led the portfolio construction and risk management of healthcare-dedicated funds as a Portfolio Manager at multiple firms. Dr. Tung earned B.A. and B.S. degrees in economics and biology, respectively, from The George Washington University, and a combined M.D./M.B.A. degree from Tufts University School of Medicine. He is a licensed physician in the states of Massachusetts and New York.
About vTv Therapeutics
vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules into different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage.
Cadisegliatin is under investigation and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Forward-Looking Statement
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.
Investor Contact
Sandya von der Weid
LifeSci Advisors, LLC
svonderweid@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
FAQ
Who is the new CFO of vTv Therapeutics (VTVT)?
What is the current status of VTVT's cadisegliatin Phase 3 trial?
What is Dr. Michael Tung's professional background before joining VTVT?
What is cadisegliatin being developed for by VTVT?
